Ohio University

skip to main content

Eli Lilly drug discovery program offers new services to OHIO researchers

From staff reports | May 26, 2017

Eli Lilly’s Open Innovation and Drug Discovery (OIDD) Program has expanded the services available to Ohio University researchers. In addition to Lilly’s cloud-based computer simulation tools, in vitro data screening and a library of compounds, researchers now have access to the Emerging Biology program and the Elanco Animal Health screening.

The Emerging Biology program offers access to the Lilly Biology Interrogation Compounds (BIC) Cassette, which provides a mechanism for exploring novel biological hypotheses. The Elanco Animal Health program gives researchers the opportunity to submit compounds for screening in proprietary assays.

The Neglected and Tropical Diseases program also has expanded to include screening against tuberculosis, Leishmaniasis and Chagas disease in partnership with the Tres Cantos Open Lab Foundation (TCOLF).

Finally, researchers now are able to submit larger molecules for screening. These compounds must contain between 40 and 85 heavy atoms with a maximum molecular weight of approximately 1200 Daltons.

For additional details on these expanded offerings or to gain access to the OIDD Program, please contact Korie Counts, technology commercialization manager in the Technology Transfer Office and affiliation coordinator for the OIDD Program at (740) 593-0977 or counts@ohio.edu.